Phase 2 Metastatic Breast Cancer Clinical Trials
83 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 83 trials
Recruiting
Phase 2
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Breast CancerMetastatic Breast CancerBreast Neoplasms+6 more
Kristina A. Fanucci297 enrolled1 locationNCT07222215
Recruiting
Phase 1Phase 2
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Breast CancerMetastatic Breast CancerBreast Cancer Female+2 more
Kristina A. Fanucci65 enrolled1 locationNCT07198724
Recruiting
Phase 2
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
Metastatic Breast CancerHER2-negative Breast CancerMetaplastic Breast Carcinoma+1 more
The Methodist Hospital Research Institute36 enrolled3 locationsNCT05660083
Recruiting
Phase 2
HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
Metastatic Breast CancerMetastatic Solid Cancer
Abscint NV/SA60 enrolled7 locationsNCT06369831
Recruiting
Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
Metastatic Breast CancerLeptomeningeal Disease
Wake Forest University Health Sciences16 enrolled3 locationsNCT02422641
Recruiting
Phase 2
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Metastatic Breast Cancer in the Liver
Delcath Systems Inc.90 enrolled5 locationsNCT06875128
Recruiting
Phase 1Phase 2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Metastatic Breast CancerColorectal, CancerEsophageal Adenocarcinoma+2 more
Boehringer Ingelheim768 enrolled108 locationsNCT06324357
Recruiting
Phase 2
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
HER2-positive Metastatic Breast CancerAdvanced/Metastatic Breast Cancer
Sun Yat-sen University57 enrolled1 locationNCT07610720
Recruiting
Phase 2
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Breast CancerTriple-Negative Breast CancerMetastatic Breast Cancer+2 more
UNC Lineberger Comprehensive Cancer Center700 enrolled2 locationsNCT07340541
Recruiting
Phase 2
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
Metastatic Breast Cancer
Merck Sharp & Dohme LLC120 enrolled41 locationsNCT06428396
Recruiting
Phase 1Phase 2
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Metastatic Breast CancerLocally Advanced Breast CancerUnresectable Breast Carcinoma
BioNTech SE380 enrolled41 locationsNCT06827236
Recruiting
Phase 2
A Study of Surgery and Radiotherapy in People With Breast Cancer
Metastatic Breast CancerHER2-positive Breast Cancer
Memorial Sloan Kettering Cancer Center178 enrolled7 locationsNCT07053085
Recruiting
Phase 1Phase 2
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center54 enrolled7 locationsNCT06110793
Recruiting
Phase 2
Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
Metastatic Breast CancerAnatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor-positive Breast Cancer+1 more
Mayo Clinic35 enrolled1 locationNCT06525766
Recruiting
Phase 2
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Unresectable Locally Recurrent Breast CancerUnresectable Locally Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.150 enrolled1 locationNCT07497386
Recruiting
Phase 2
HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
HER2-positive Metastatic Breast CancerHER2-positive Advanced Breast Cancer
Jules Bordet Institute87 enrolled1 locationNCT06595563
Recruiting
Phase 2
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Triple-Negative Breast CancerMetastatic Breast CancerEstrogen-receptor-low Breast Cancer
Kathy Miller168 enrolled6 locationsNCT05846789
Recruiting
Phase 2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled141 locationsNCT06157892
Recruiting
Phase 2
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
Metastatic Breast Cancer
Dartmouth-Hitchcock Medical Center36 enrolled1 locationNCT05716516
Recruiting
Phase 1Phase 2
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Metastatic Breast CancerHR+/HER2-negative Breast Cancer
SynDevRx, Inc.52 enrolled10 locationsNCT05455619